Growth Hormone – Hormone Replacement for the Somatopause?Savine R. · Sönksen P.
Department of Medicine, St Thomas’ Hospital, London, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Twenty-four-hour growth hormone (GH) secretion reaches a peak at around puberty and by the age of 21 has begun to decrease. Thereafter the fall in GH secretion is progressive such that by the age of 60 most adults have total 24-hour secretion rates indistinguishable from those of hypopituitary patients with organic lesions in the pituitary gland. Patterns of GH secretion are similar to those in younger people but GH pulses are markedly reduced in amplitude. Sleep and exercise remain the major stimuli for GH secretion. The fall in GH secretion seen with ageing coincides with changes in body composition and lipid metabolism that are similar to those seen in adults with GH deficiency. In elderly subjects, although GH secretion is markedly reduced, remaining GH secretion correlates closely with body composition (particularly with lean body mass and inversely with central abdominal fat). Pioneering studies carried out by Rudman showed that GH administration to elderly subjects with low insulin-like growth factor-I levels resulted in reversal of many of the changes associated with GH deficiency, namely an increase in lean body mass and bone mineral density and a reduction in body fat and plasma cholesterol. These changes were remarkably similar to those shown a year earlier in adults with GH deficiency given GH replacement. Subsequent studies of GH replacement in elderly adults have confirmed Rudman’s initial observations but have been dominated by side effects which have led to a high number of dropouts. It is now clear that the elderly are very sensitive to GH and the doses used need to be very low, increased very slowly and tailored to the individual needs of each patient. Using this more cautious approach, recent studies have been very positive. A series of papers from Blackman’s group, presented at the US endocrine meeting in San Diego in 1999, investigated the effects of GH with or without testosterone supplements (in men) and oestrogen supplements (in women). Their results showed positive effects of GH on lean body mass, central fat, low-density lipoprotein cholesterol and aerobic capacity. In many instances there was a positive interaction between GH and hormone replacement with testosterone and oestrogen, but it appeared that GH showed the most potent anabolic effects. Clearly more studies are needed before GH replacement for the elderly becomes established. Safety issues will require close scrutiny, but the data available so far are sufficiently positive to undertake large multicentre, placebo-controlled trials, particularly looking at endpoints associated with prevention of frailty and loss of independence.
© 2000 S. Karger AG, Basel
Toogood AA, O’Neill PA, Shalet SM: Beyond the somatopause: Growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996;82:460–465.
- Saloman F, Cuneo RC, Hesp R, Sönksen PH: The effects of treatment with recombinant growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797–1803.
Cuneo RC, Saloman F, Wiles CM, Sönksen PH: Skeletal muscle performance in adults with growth hormone deficiency. Horm Res 1990;33(suppl 4):55–60.
- Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson B-Å: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137:240–245.
Christ E, Cummings M, Russell-Jones D: Dyslipidaemia in adult growth hormone deficiency and the effect of GH replacement: A review. Trends Endocrinol Metab 1998;9(5):200–206.
- Erfurth EM, Bülow B, Ekilsson J, Hagmar L: High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: Preliminary results. Growth Horm IGF Res 1999;9:21–24.
- Cuneo RC, Saloman F, Wiles CM, Hesp R, Sönksen PH: Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance. J Appl Physiol 1991;70:695–700.
Russell-Jones DL, Watts GF, Weissberger A, Naoumova A, Myers J, Thompson GR, Sönksen PH: The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol 1994;41:345–350.
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J: Effect of long term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol 1998;48:561–568.
- Zadik Z, Calew SA, McCarter RJ, Meistas M, Kowarski AA: The influence of age on the 24-hour integrated growth hormone concentration in normal individuals. J Clin Endocrinol Metab 1985;60:137–140.
Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson B-Å: Serum insulin-like growth factor I in a random population of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1996;41:2209–2215.
- Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone on men over 60 years old. N Engl J Med 1990;323:1–6.
Young A: Muscle function in old age. New Iss Neurosci 1998;I:141–156, 235–266.
- Skelton DA, Grieg CA, Davies JM, Young A: Strength, power and related functional ability of healthy people aged 60–89 years. Age Ageing 1994;23:371–377.
- Bohannon RW: Comfortable and maximum walking speed of adults aged 20–79 years: Reference values and determinants. Age Ageing 1997;26:15–19.
O’Connor: PhD thesis, Dublin, 1998.
Vahl N, Jørgensen JO, Jurik AG, Christiansen JS: Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated growth hormone secretion in healthy adults. J Clin Endocrinol Metab 1997;816:2209–2215.
- Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C: Programming of growth hormone secretion and bone density in elderly men: A hypothesis. J Clin Endocrinol Metab 1998;83:135–139.
Sturgess I, Martin FC: Correlation of techniques of body composition, estimation of muscle strength and insulin-like growth factor I in fit elderly subjects. 15th World Congress of Gerontology, 1993.
Papdakis MA, Grady D, Tierney M: Insulin-like growth factor I and functional status in elderly men. J Am Geriatr Soc 1994;42:1350–1355.
Hartman ML, Clasey CL, Weltman JY, Wilderman L, Kannaley JA, Freund SB, Teates CD, Bouchard C, Thornton MO, Weltman A: Fitness is related to 24-hour GH release in men but not women. Endocrinol Metab 1997;4(suppl A):90.
Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW: Effects of human growth hormone on body composition in elderly men. Horm Res 1991;36(suppl 1):73–81.
- Karlsson C, Stenlof K, Gudmundar Johansson PM, Björntorp P, Bengtsson B-Å, Carlsson B, Carlsson L, Sjöström L: Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men. Eur J Endocrinol 1998;138:408–414.
Welle S, Thornton C, Stott M, McHenry B: Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996;83:3239–3244.
- Papdakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, Grunfeld C: Growth hormone replacement in healthy older men improves body composition, but not functional ability. Ann Intern Med 1996;124:708–716.
- Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R: Effects of recombinant human growth hormone on metabolic indices, body composition and bone turnover in healthy elderly men. J Clin Endocrinol Metab 1994;79:470–479.
- Holloway L, Kohleier L, Kent K, Marcus R: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997;82:1111–1117.
Yarasheski KE, Campbell JA, Kohrt WM: Effect of resistance exercise and growth hormone on bone density in older men. Clin Endocrinol 1997;47:223–229.
Weissberger AJ, Anastasiadis AD, Sturgess I, Martin FC, Smith MA, Sönksen PH: Recombinant human growth hormone (GH) treatment in elderly patients undergoing total hip replacement: Effects on muscle mass and strength. Endocrinol Metab 1997;4(suppl A):18.
Ahlmen J, Johnsson G, Johansson A, Bengtsson B-Å: Beneficial effects of growth hormone treatment in elderly patients on dialysis. Endocrinol Metab 1997;4(suppl A):18.
Veldhuis JD, Iranmanesh A: Physiological regulation of the human growth hormone (GH) insulin-like growth factor type I (IGF-I) axis: Predominant impact of age, obesity, gonadal function and sleep. Sleep 1996;19(suppl 10):S221–S224.
- Guldner J, Scheir T, Friess E, Colla M, Holsboer F, Steiger A: Reduced efficacy of growth hormone releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging 1997;18:491–495.
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellatoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG: Effects of single nightly injections of growth hormone releasing hormone (GHRH 1-29) in healthy elderly men. Metab Clin Exp 1997;46:89–96.
- Corpas E, Harman SM, Pineyro MA, Robertson R, Blackman MR: Growth hormone (GH)-releasing hormone (1-29) twice daily reverses the decreased GH and insulin-like growth factor I levels in old men. J Clin Endocrinol Metab 1992;75:530–535.
- Corpas E, Harman SM, Pineyro MA, Robertson R, Blackman MR: Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor I levels in old men. J Clin Endocrinol Metab 1993;76:134–138.
- Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996;81:4249–4257.
- Hobbs CJ, Plymate SR, Rosen CJ, Adler RA: Testosterone administration increases IGF-I in normal men. J Clin Endocrinol Metab 1993;77:776–779.
- Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA: GH deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82:550–555.
- Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO: Both oral and transdermal oestrogen increase growth hormone release in post-menopausal women: A clinical research center study. J Clin Endocrinol Metab 1996;81:2250–2256.
- Bellatoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR: Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: A clinical research center study. J Clin Endocrinol Metab 1996;81:2848–2853.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.